TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03041727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Description: Fascial Manipulation is a manual therapy that focused on deep muscular fascial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercises protocol
Description: Stretching and strengthening exercises
Study: NCT03898648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting room task
Description: The waiting room task consists in a computerized neuropsychological task in which the participant is asked to freely choose a chair to sit in a waiting room. In a row of four chairs, the two in the middle are occupied by two males or females. One of the two subjects sitting either has a neutral face, or express a negative emotion (fear or anger).~To make their decision, participants must press the S keyboard button to go left or the L keyboard button to go right in a time limit of 1500 milliseconds.~One third of the time, the cursor moves in the opposite direction to that requested by the participant. For example, if the subject presses S, the cursor moves to the right instead of to the left.~Those reverse trials are used to evaluate their motivation to correct the movement of the cursor.~The participant will repeat the task 360 times for the assessment to be completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting room task
Description: The waiting room task consists in a computerized neuropsychological task in which the participant is asked to freely choose a chair to sit in a waiting room. In a row of four chairs, the two in the middle are occupied by two males or females. One of the two subjects sitting either has a neutral face, or express a negative emotion (fear or anger).~To make their decision, participants must press the S keyboard button to go left or the L keyboard button to go right in a time limit of 1500 milliseconds.~One third of the time, the cursor moves in the opposite direction to that requested by the participant. For example, if the subject presses S, the cursor moves to the right instead of to the left.~Those reverse trials are used to evaluate their motivation to correct the movement of the cursor.~The participant will repeat the task 360 times for the assessment to be completed.
Study: NCT03176849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
Study: NCT03250026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace convergence dialogue
Description: Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
Study: NCT03176849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Vitamin D3 Supplementation
Description: Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vitamin D3 Supplementation
Description: Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally.
Study: NCT00957541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paradym CRT + Physiological Diagnosis (PhD)
Description: All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
Study: NCT03865472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Undergo rTMS

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham rTMS
Study: NCT02338843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJPC-501
Description: Treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBO
Study: NCT00656305

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ExAblate MRfFUS
Description: MR guided focused ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRfFUS
Description: MR guided focused ultrasound.
Study: NCT01542307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen is inhaled for 30 minutes during migraine attack

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Placebo
Study: NCT00656305

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: sham comparator
Study: NCT00833339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: 600 mg/day x 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03626298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide, ABA and Zinc PCA
Description: combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
Study: NCT03250026

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Manager
Description: Regular contact Care Manager during around 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Manager
Description: Regular contact Care Manager during around 12 weeks
Study: NCT01591460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: 800 mg three times daily for 24, 32 or 44 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg subcutaneously once a week for 24, 32 or 44 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg subcutaneously once a week for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (Copegus]
Description: 1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
Study: NCT04776850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study: NCT00010205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzoylphenylurea
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01310920

Intervention type: OTHER
Intervention: observation
Description: genotyping
Study: NCT02987985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen, gabapentin
Description: acetaminophen 15 mg/kg, gabapentin 10 mg/kg
Study: NCT01591460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (Copegus]
Description: 1000 mg or 1200 mg orally once a day for 4 weeks
Study: NCT03739242

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination
Description: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
Study: NCT02276027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
Study: NCT02987985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen 15 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine , Lidocaine , Dexmedetomidine
Description: Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl, Dexmedetomidine
Description: Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone , Ondansetron
Description: Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone , Ondansetron
Description: Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane (dose titrated to effect)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane, Fentanyl
Description: Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
Study: NCT02061917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco-Heating Cigarette
Description: Smokers switched to a tobacco-heating cigarette for 24 weeks
Study: NCT02276027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
Study: NCT01054690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bactiguard Infection Protection (BIP) Cathter.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Silicone Urinary Catheter
Study: NCT01759680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrosphère device
Description: Vertical Sinusoidal vibration
Study: NCT03376503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: PK,PD and safety assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: PK,PD and safety assessment
Study: NCT00199030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (MabCampath)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (MabCampath)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Study: NCT04776850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study: NCT02061917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snus (Smokeless Tobacco)
Description: Smokers switched to snus product for 24 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco-Burning Cigarette
Description: Smokers switched to a tobacco-burning cigarette for 24 weeks
Study: NCT00929929

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-leucine.
Description: 10 g of leucine per day, during 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin.
Description: 10 g of maltodextrin per day, during 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program.
Description: Progressive resistance exercise program 4 days a week, during 12 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise program.
Description: Progressive resistance exercise program 4 days a week, during 12 weeks.
Study: NCT00635492

Intervention type: DRUG
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day

Intervention type: DRUG
Intervention: any human insulin or analog insulin(s) given in any regimen by subcutaneous injection
Study: NCT01789385

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
Study: NCT03433430

Intervention type: DEVICE
Group type: OTHER
Intervention: truSculpt
Description: Subjects will receive utreatments and will be followed at 12 weeks post final treatment.
Study: NCT04050930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mastication
Description: Simultaneous recordings of postprandial thermogenesis (gas exchange), cardiac activity (ECG), masticatory muscle contraction (EMG), and blood collection, during alternating periods of no-mastication or mastication of natural foods or chewing gums of different hardness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mastication
Description: Simultaneous recordings of postprandial thermogenesis (gas exchange), cardiac activity (ECG), masticatory muscle contraction (EMG), and blood collection, during alternating periods of no-mastication or mastication of natural foods or chewing gums of different hardness
Study: NCT01814930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief standardized contraceptive counseling intervention
Description: The intervention employed an in-person counseling strategy that included empowerment messaging and an instrument to clarify the participants' preferences for contraception in the context of their goals for future childbearing.
Study: NCT04738071

Intervention type: DEVICE
Intervention: PFO closure
Description: PFO closure after stroke or transient ischemic attack

Intervention type: DEVICE
Intervention: PFO closure
Description: PFO closure after stroke or transient ischemic attack

Intervention type: DEVICE
Intervention: PFO closure
Description: PFO closure after stroke or transient ischemic attack

Intervention type: DEVICE
Intervention: PFO closure
Description: PFO closure after stroke or transient ischemic attack

Intervention type: DEVICE
Intervention: PFO closure
Description: PFO closure after stroke or transient ischemic attack
Study: NCT01313780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone
Description: Dose and administration : Upto 40mg B.I.D per daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone(single compound)
Description: Dose and administration : Upto 40mg B.I.D per daily.
Study: NCT04776850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lapine T-Lymphocyte Immune Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Undergo plasmapheresis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study: NCT02407535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Description: Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
Study: NCT03804541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
Study: NCT02768376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Fentanyl (Spinal Anesthesia)
Description: Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
Study: NCT02162888

Intervention type: DRUG
Group type: OTHER
Intervention: Test Product (Bendamustine)

Intervention type: DRUG
Group type: OTHER
Intervention: Test Product (Bendamustine)

Intervention type: DRUG
Group type: OTHER
Intervention: Test Product (Bendamustine)
Study: NCT02221089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escherichia coli Endotoxin
Description: dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escherichia coli Endotoxin
Description: dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Retaron®
Description: Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to Retaron capsules
Study: NCT04378166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart glass
Description: Practitioner wears smart glasses connected to ultrasound machine during central venous catheterization
Study: NCT02433977

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated Linolenic Acid
Description: CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
Study: NCT02276027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
Study: NCT02433977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrate
Description: Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
Study: NCT02603796

Intervention type: OTHER
Intervention: 3D Scan of nares
Description: 3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
Study: NCT00170001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: 40 mg bid dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 40 mg BID
Study: NCT00791076

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2pmol/kg-1/min-1 placebo infused continuously over 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Polypeptide (PP)
Description: 2pmol/kg-1/min-1 PP infused continuously over 72 hours.
Study: NCT04023929

Intervention type: PROCEDURE
Intervention: Cord blood sampling
Description: A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.

Intervention type: PROCEDURE
Intervention: Cord blood sampling
Description: A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.

Intervention type: PROCEDURE
Intervention: Cord blood sampling
Description: A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
Study: NCT02361476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Injection - during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection - during surgery
Study: NCT01857596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion, Lorexys low-dose, Lorexys moderate-dose
Description: Lorexys is a proprietary fixed-dose combination of two agents
Study: NCT00813969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cell transplantation
Description: A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
Study: NCT03390101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085 Q2W
Description: In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085 Q4W
Description: In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54.